Catalysts / DFTX
Upcoming FDA decisions and readouts we track for Definium Therapeutics, each with the filing that announced it.
FreeBioList tracks 2 catalysts for Definium Therapeutics (DFTX, listed on Nasdaq): 1 upcoming and 1 decided. Both concern DT120 ODT (Generalised anxiety disorder; Major depressive disorder).
First on the list: the Phase 3 readout for DT120 ODT (Major depressive disorder), guided by the company to 2027.
Decided and on record:
Each outcome links to the filing or notice that reported it in the table below.
Both rows link to SEC filings (8-K or 6-K). Both have been verified by a person reading the filing itself, most recently on 14 Sep 2026. The methodology page explains each status.
Background reading: How to read a Phase 3 topline readout.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| Definium Therapeutics DFTX · Nasdaq | DT120 ODT | Generalised anxiety disorder | Sep 2026 company guidance |
Phase 3 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
| Definium Therapeutics DFTX · Nasdaq | DT120 ODT | Major depressive disorder | 2027 company guidance |
Phase 3 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
FreeBioList